Ethandrostate
Clinical data | |
---|---|
Other names | Ethynylandrostenediol 3 |
Routes of administration | By mouth, intramuscular injection |
Drug class | Estrogen |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C30H44O3 |
Molar mass | 452.679 g·mol−1 |
3D model (JSmol) | |
| |
|
Ethandrostate, also known as ethinylandrostenediol 3
Ligand | Other names | Relative binding affinities (RBA, %)a | Absolute binding affinities (Ki, nM)a | Action | ||
---|---|---|---|---|---|---|
ER |
ER |
ER |
ER | |||
Estradiol | E2; 17 |
100 | 100 | 0.115 (0.04–0.24) | 0.15 (0.10–2.08) | Estrogen |
Estrone | E1; 17-Ketoestradiol | 16.39 (0.7–60) | 6.5 (1.36–52) | 0.445 (0.3–1.01) | 1.75 (0.35–9.24) | Estrogen |
Estriol | E3; 16 |
12.65 (4.03–56) | 26 (14.0–44.6) | 0.45 (0.35–1.4) | 0.7 (0.63–0.7) | Estrogen |
Estetrol | E4; 15 |
4.0 | 3.0 | 4.9 | 19 | Estrogen |
Alfatradiol | 17 |
20.5 (7–80.1) | 8.195 (2–42) | 0.2–0.52 | 0.43–1.2 | Metabolite |
16-Epiestriol | 16 |
7.795 (4.94–63) | 50 | ? | ? | Metabolite |
17-Epiestriol | 16 |
55.45 (29–103) | 79–80 | ? | ? | Metabolite |
16,17-Epiestriol | 16 |
1.0 | 13 | ? | ? | Metabolite |
2-Hydroxyestradiol | 2-OH-E2 | 22 (7–81) | 11–35 | 2.5 | 1.3 | Metabolite |
2-Methoxyestradiol | 2-MeO-E2 | 0.0027–2.0 | 1.0 | ? | ? | Metabolite |
4-Hydroxyestradiol | 4-OH-E2 | 13 (8–70) | 7–56 | 1.0 | 1.9 | Metabolite |
4-Methoxyestradiol | 4-MeO-E2 | 2.0 | 1.0 | ? | ? | Metabolite |
2-Hydroxyestrone | 2-OH-E1 | 2.0–4.0 | 0.2–0.4 | ? | ? | Metabolite |
2-Methoxyestrone | 2-MeO-E1 | <0.001–<1 | <1 | ? | ? | Metabolite |
4-Hydroxyestrone | 4-OH-E1 | 1.0–2.0 | 1.0 | ? | ? | Metabolite |
4-Methoxyestrone | 4-MeO-E1 | <1 | <1 | ? | ? | Metabolite |
16 |
16 |
2.0–6.5 | 35 | ? | ? | Metabolite |
2-Hydroxyestriol | 2-OH-E3 | 2.0 | 1.0 | ? | ? | Metabolite |
4-Methoxyestriol | 4-MeO-E3 | 1.0 | 1.0 | ? | ? | Metabolite |
Estradiol sulfate | E2S; Estradiol 3-sulfate | <1 | <1 | ? | ? | Metabolite |
Estradiol disulfate | Estradiol 3,17 |
0.0004 | ? | ? | ? | Metabolite |
Estradiol 3-glucuronide | E2-3G | 0.0079 | ? | ? | ? | Metabolite |
Estradiol 17 |
E2-17G | 0.0015 | ? | ? | ? | Metabolite |
Estradiol 3-gluc. 17 |
E2-3G-17S | 0.0001 | ? | ? | ? | Metabolite |
Estrone sulfate | E1S; Estrone 3-sulfate | <1 | <1 | >10 | >10 | Metabolite |
Estradiol benzoate | EB; Estradiol 3-benzoate | 10 | ? | ? | ? | Estrogen |
Estradiol 17 |
E2-17B | 11.3 | 32.6 | ? | ? | Estrogen |
Estrone methyl ether | Estrone 3-methyl ether | 0.145 | ? | ? | ? | Estrogen |
ent-Estradiol | 1-Estradiol | 1.31–12.34 | 9.44–80.07 | ? | ? | Estrogen |
Equilin | 7-Dehydroestrone | 13 (4.0–28.9) | 13.0–49 | 0.79 | 0.36 | Estrogen |
Equilenin | 6,8-Didehydroestrone | 2.0–15 | 7.0–20 | 0.64 | 0.62 | Estrogen |
17 |
7-Dehydro-17 |
7.9–113 | 7.9–108 | 0.09 | 0.17 | Estrogen |
17 |
7-Dehydro-17 |
18.6 (18–41) | 14–32 | 0.24 | 0.57 | Estrogen |
17 |
6,8-Didehydro-17 |
35–68 | 90–100 | 0.15 | 0.20 | Estrogen |
17 |
6,8-Didehydro-17 |
20 | 49 | 0.50 | 0.37 | Estrogen |
8,9-Dehydro-17 |
68 | 72 | 0.15 | 0.25 | Estrogen | |
8,9-Dehydroestrone | 19 | 32 | 0.52 | 0.57 | Estrogen | |
Ethinylestradiol | EE; 17 |
120.9 (68.8–480) | 44.4 (2.0–144) | 0.02–0.05 | 0.29–0.81 | Estrogen |
Mestranol | EE 3-methyl ether | ? | 2.5 | ? | ? | Estrogen |
Moxestrol | RU-2858; 11 |
35–43 | 5–20 | 0.5 | 2.6 | Estrogen |
Methylestradiol | 17 |
70 | 44 | ? | ? | Estrogen |
Diethylstilbestrol | DES; Stilbestrol | 129.5 (89.1–468) | 219.63 (61.2–295) | 0.04 | 0.05 | Estrogen |
Hexestrol | Dihydrodiethylstilbestrol | 153.6 (31–302) | 60–234 | 0.06 | 0.06 | Estrogen |
Dienestrol | Dehydrostilbestrol | 37 (20.4–223) | 56–404 | 0.05 | 0.03 | Estrogen |
Benzestrol (B2) | – | 114 | ? | ? | ? | Estrogen |
Chlorotrianisene | TACE | 1.74 | ? | 15.30 | ? | Estrogen |
Triphenylethylene | TPE | 0.074 | ? | ? | ? | Estrogen |
Triphenylbromoethylene | TPBE | 2.69 | ? | ? | ? | Estrogen |
Tamoxifen | ICI-46,474 | 3 (0.1–47) | 3.33 (0.28–6) | 3.4–9.69 | 2.5 | SERM |
Afimoxifene | 4-Hydroxytamoxifen; 4-OHT | 100.1 (1.7–257) | 10 (0.98–339) | 2.3 (0.1–3.61) | 0.04–4.8 | SERM |
Toremifene | 4-Chlorotamoxifen; 4-CT | ? | ? | 7.14–20.3 | 15.4 | SERM |
Clomifene | MRL-41 | 25 (19.2–37.2) | 12 | 0.9 | 1.2 | SERM |
Cyclofenil | F-6066; Sexovid | 151–152 | 243 | ? | ? | SERM |
Nafoxidine | U-11,000A | 30.9–44 | 16 | 0.3 | 0.8 | SERM |
Raloxifene | – | 41.2 (7.8–69) | 5.34 (0.54–16) | 0.188–0.52 | 20.2 | SERM |
Arzoxifene | LY-353,381 | ? | ? | 0.179 | ? | SERM |
Lasofoxifene | CP-336,156 | 10.2–166 | 19.0 | 0.229 | ? | SERM |
Ormeloxifene | Centchroman | ? | ? | 0.313 | ? | SERM |
Levormeloxifene | 6720-CDRI; NNC-460,020 | 1.55 | 1.88 | ? | ? | SERM |
Ospemifene | Deaminohydroxytoremifene | 0.82–2.63 | 0.59–1.22 | ? | ? | SERM |
Bazedoxifene | – | ? | ? | 0.053 | ? | SERM |
Etacstil | GW-5638 | 4.30 | 11.5 | ? | ? | SERM |
ICI-164,384 | – | 63.5 (3.70–97.7) | 166 | 0.2 | 0.08 | Antiestrogen |
Fulvestrant | ICI-182,780 | 43.5 (9.4–325) | 21.65 (2.05–40.5) | 0.42 | 1.3 | Antiestrogen |
Propylpyrazoletriol | PPT | 49 (10.0–89.1) | 0.12 | 0.40 | 92.8 | ER |
16 |
16 |
14.6–57 | 0.089 | 0.27 | 131 | ER |
16 |
16 |
30.2 | 2.30 | ? | ? | ER |
Methylpiperidinopyrazole | MPP | 11 | 0.05 | ? | ? | ER |
Diarylpropionitrile | DPN | 0.12–0.25 | 6.6–18 | 32.4 | 1.7 | ER |
8 |
8 |
0.35 | 22.0–83 | 12.9 | 0.50 | ER |
Prinaberel | ERB-041; WAY-202,041 | 0.27 | 67–72 | ? | ? | ER |
ERB-196 | WAY-202,196 | ? | 180 | ? | ? | ER |
Erteberel | SERBA-1; LY-500,307 | ? | ? | 2.68 | 0.19 | ER |
SERBA-2 | – | ? | ? | 14.5 | 1.54 | ER |
Coumestrol | – | 9.225 (0.0117–94) | 64.125 (0.41–185) | 0.14–80.0 | 0.07–27.0 | Xenoestrogen |
Genistein | – | 0.445 (0.0012–16) | 33.42 (0.86–87) | 2.6–126 | 0.3–12.8 | Xenoestrogen |
Equol | – | 0.2–0.287 | 0.85 (0.10–2.85) | ? | ? | Xenoestrogen |
Daidzein | – | 0.07 (0.0018–9.3) | 0.7865 (0.04–17.1) | 2.0 | 85.3 | Xenoestrogen |
Biochanin A | – | 0.04 (0.022–0.15) | 0.6225 (0.010–1.2) | 174 | 8.9 | Xenoestrogen |
Kaempferol | – | 0.07 (0.029–0.10) | 2.2 (0.002–3.00) | ? | ? | Xenoestrogen |
Naringenin | – | 0.0054 (<0.001–0.01) | 0.15 (0.11–0.33) | ? | ? | Xenoestrogen |
8-Prenylnaringenin | 8-PN | 4.4 | ? | ? | ? | Xenoestrogen |
Quercetin | – | <0.001–0.01 | 0.002–0.040 | ? | ? | Xenoestrogen |
Ipriflavone | – | <0.01 | <0.01 | ? | ? | Xenoestrogen |
Miroestrol | – | 0.39 | ? | ? | ? | Xenoestrogen |
Deoxymiroestrol | – | 2.0 | ? | ? | ? | Xenoestrogen |
– | <0.001–0.0875 | <0.001–0.016 | ? | ? | Xenoestrogen | |
Resveratrol | – | <0.001–0.0032 | ? | ? | ? | Xenoestrogen |
– | 48 (13–52.5) | ? | ? | ? | Xenoestrogen | |
– | 0.6 (0.032–13) | ? | ? | ? | Xenoestrogen | |
Zeranol | 48–111 | ? | ? | ? | Xenoestrogen | |
Taleranol | 16 (13–17.8) | 14 | 0.8 | 0.9 | Xenoestrogen | |
Zearalenone | ZEN | 7.68 (2.04–28) | 9.45 (2.43–31.5) | ? | ? | Xenoestrogen |
Zearalanone | ZAN | 0.51 | ? | ? | ? | Xenoestrogen |
Bisphenol A | BPA | 0.0315 (0.008–1.0) | 0.135 (0.002–4.23) | 195 | 35 | Xenoestrogen |
Endosulfan | EDS | <0.001–<0.01 | <0.01 | ? | ? | Xenoestrogen |
Kepone | Chlordecone | 0.0069–0.2 | ? | ? | ? | Xenoestrogen |
o,p'-DDT | – | 0.0073–0.4 | ? | ? | ? | Xenoestrogen |
p,p'-DDT | – | 0.03 | ? | ? | ? | Xenoestrogen |
Methoxychlor | p,p'-Dimethoxy-DDT | 0.01 (<0.001–0.02) | 0.01–0.13 | ? | ? | Xenoestrogen |
HPTE | Hydroxychlor; p,p'-OH-DDT | 1.2–1.7 | ? | ? | ? | Xenoestrogen |
Testosterone | T; 4-Androstenolone | <0.0001–<0.01 | <0.002–0.040 | >5000 | >5000 | Androgen |
Dihydrotestosterone | DHT; 5 |
0.01 (<0.001–0.05) | 0.0059–0.17 | 221–>5000 | 73–1688 | Androgen |
Nandrolone | 19-Nortestosterone; 19-NT | 0.01 | 0.23 | 765 | 53 | Androgen |
Dehydroepiandrosterone | DHEA; Prasterone | 0.038 (<0.001–0.04) | 0.019–0.07 | 245–1053 | 163–515 | Androgen |
5-Androstenediol | A5; Androstenediol | 6 | 17 | 3.6 | 0.9 | Androgen |
4-Androstenediol | – | 0.5 | 0.6 | 23 | 19 | Androgen |
4-Androstenedione | A4; Androstenedione | <0.01 | <0.01 | >10000 | >10000 | Androgen |
3 |
3 |
0.07 | 0.3 | 260 | 48 | Androgen |
3 |
3 |
3 | 7 | 6 | 2 | Androgen |
Androstanedione | 5 |
<0.01 | <0.01 | >10000 | >10000 | Androgen |
Etiocholanedione | 5 |
<0.01 | <0.01 | >10000 | >10000 | Androgen |
Methyltestosterone | 17 |
<0.0001 | ? | ? | ? | Androgen |
Ethinyl-3 |
17 |
4.0 | <0.07 | ? | ? | Estrogen |
Ethinyl-3 |
17 |
50 | 5.6 | ? | ? | Estrogen |
Progesterone | P4; 4-Pregnenedione | <0.001–0.6 | <0.001–0.010 | ? | ? | Progestogen |
Norethisterone | NET; 17 |
0.085 (0.0015–<0.1) | 0.1 (0.01–0.3) | 152 | 1084 | Progestogen |
Norethynodrel | 5(10)-Norethisterone | 0.5 (0.3–0.7) | <0.1–0.22 | 14 | 53 | Progestogen |
Tibolone | 7 |
0.5 (0.45–2.0) | 0.2–0.076 | ? | ? | Progestogen |
7 |
0.069–<0.1 | 0.027–<0.1 | ? | ? | Progestogen | |
3 |
– | 2.5 (1.06–5.0) | 0.6–0.8 | ? | ? | Progestogen |
3 |
– | 1.6 (0.75–1.9) | 0.070–0.1 | ? | ? | Progestogen |
Footnotes: a = (1) Binding affinity values are of the format "median (range)" (# (#–#)), "range" (#–#), or "value" (#) depending on the values available. The full sets of values within the ranges can be found in the Wiki code. (2) Binding affinities were determined via displacement studies in a variety of in-vitro systems with labeled estradiol and human ER |
References
[edit]- ^ a b Elva G. Shipley (1962). "Anti-gonadotropic steroids, inhibition of ovulation and mating". In Dorfman RI (ed.). Bioassay. Elsevier. pp. 179–274. ISBN 978-1-4832-7276-4.
- ^ Boccabella A, Bakritges C (January 1956). "Effects of ethandrostate on pituitary and sex organs of rats". Anatomical Record. 124 (2): 260.
- ^ a b c d Clinton R, Neumann H, Laskowski S, Christiansen R (1957). "Notes - Esters of 17
α -Ethinyl-androstane-3β ,17β -diol and 17α -Ethinylandrost-5-ene-3β , 17β -diol". The Journal of Organic Chemistry. 22 (4): 473–475. doi:10.1021/jo01355a627. ISSN 0022-3263. - ^ a b c d Olson KB, Frawley TF, Stein AA, Shields D (1958). "Ethandrostate: endocrine effects and studies in treatment of cancer". Cancer. 11 (3): 537–45. doi:10.1002/1097-0142(195805/06)11:3<537::aid-cncr2820110313>3.0.co;2-w. PMID 13523561. S2CID 738607.